221 related articles for article (PubMed ID: 12570826)
1. Natural killer T cells as targets for therapeutic intervention in autoimmune diseases.
Wilson MT; Van Kaer L
Curr Pharm Des; 2003; 9(3):201-20. PubMed ID: 12570826
[TBL] [Abstract][Full Text] [Related]
2. Quantitative and qualitative differences in the in vivo response of NKT cells to distinct alpha- and beta-anomeric glycolipids.
Parekh VV; Singh AK; Wilson MT; Olivares-Villagómez D; Bezbradica JS; Inazawa H; Ehara H; Sakai T; Serizawa I; Wu L; Wang CR; Joyce S; Van Kaer L
J Immunol; 2004 Sep; 173(6):3693-706. PubMed ID: 15356115
[TBL] [Abstract][Full Text] [Related]
3. Regulation of immune responses by CD1d-restricted natural killer T cells.
Van Kaer L
Immunol Res; 2004; 30(2):139-53. PubMed ID: 15477656
[TBL] [Abstract][Full Text] [Related]
4. Natural killer T cells and autoimmune disease.
Wu L; Van Kaer L
Curr Mol Med; 2009 Feb; 9(1):4-14. PubMed ID: 19199937
[TBL] [Abstract][Full Text] [Related]
5. The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice.
Hong S; Wilson MT; Serizawa I; Wu L; Singh N; Naidenko OV; Miura T; Haba T; Scherer DC; Wei J; Kronenberg M; Koezuka Y; Van Kaer L
Nat Med; 2001 Sep; 7(9):1052-6. PubMed ID: 11533710
[TBL] [Abstract][Full Text] [Related]
6. Natural killer T cells as targets for immunotherapy of autoimmune diseases.
Van Kaer L
Immunol Cell Biol; 2004 Jun; 82(3):315-22. PubMed ID: 15186263
[TBL] [Abstract][Full Text] [Related]
7. Phenotypical and functional alterations during the expansion phase of invariant Valpha14 natural killer T (Valpha14i NKT) cells in mice primed with alpha-galactosylceramide.
Ikarashi Y; Iizuka A; Koshidaka Y; Heike Y; Takaue Y; Yoshida M; Kronenberg M; Wakasugi H
Immunology; 2005 Sep; 116(1):30-7. PubMed ID: 16108815
[TBL] [Abstract][Full Text] [Related]
8. alpha-Galactosylceramide therapy for autoimmune diseases: prospects and obstacles.
Van Kaer L
Nat Rev Immunol; 2005 Jan; 5(1):31-42. PubMed ID: 15630427
[TBL] [Abstract][Full Text] [Related]
9. Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes.
Sharif S; Arreaza GA; Zucker P; Mi QS; Sondhi J; Naidenko OV; Kronenberg M; Koezuka Y; Delovitch TL; Gombert JM; Leite-De-Moraes M; Gouarin C; Zhu R; Hameg A; Nakayama T; Taniguchi M; Lepault F; Lehuen A; Bach JF; Herbelin A
Nat Med; 2001 Sep; 7(9):1057-62. PubMed ID: 11533711
[TBL] [Abstract][Full Text] [Related]
10. Human invariant V alpha 24-J alpha Q TCR supports the development of CD1d-dependent NK1.1+ and NK1.1- T cells in transgenic mice.
Capone M; Cantarella D; Schümann J; Naidenko OV; Garavaglia C; Beermann F; Kronenberg M; Dellabona P; MacDonald HR; Casorati G
J Immunol; 2003 Mar; 170(5):2390-8. PubMed ID: 12594262
[TBL] [Abstract][Full Text] [Related]
11. Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis.
Singh AK; Wilson MT; Hong S; Olivares-Villagómez D; Du C; Stanic AK; Joyce S; Sriram S; Koezuka Y; Van Kaer L
J Exp Med; 2001 Dec; 194(12):1801-11. PubMed ID: 11748281
[TBL] [Abstract][Full Text] [Related]
12. iNKT-cell responses to glycolipids.
Parekh VV; Wilson MT; Van Kaer L
Crit Rev Immunol; 2005; 25(3):183-213. PubMed ID: 16048435
[TBL] [Abstract][Full Text] [Related]
13. Human NKT cells express granulysin and exhibit antimycobacterial activity.
Gansert JL; Kiessler V; Engele M; Wittke F; Röllinghoff M; Krensky AM; Porcelli SA; Modlin RL; Stenger S
J Immunol; 2003 Mar; 170(6):3154-61. PubMed ID: 12626573
[TBL] [Abstract][Full Text] [Related]
14. A subset of NKT cells that lacks the NK1.1 marker, expresses CD1d molecules, and autopresents the alpha-galactosylceramide antigen.
Hameg A; Apostolou I; Leite-De-Moraes M; Gombert JM; Garcia C; Koezuka Y; Bach JF; Herbelin A
J Immunol; 2000 Nov; 165(9):4917-26. PubMed ID: 11046017
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic potential of glycolipid ligands for natural killer (NK) T cells in the suppression of autoimmune diseases.
Miyake S; Yamamura T
Curr Drug Targets Immune Endocr Metabol Disord; 2005 Sep; 5(3):315-22. PubMed ID: 16178791
[TBL] [Abstract][Full Text] [Related]
16. The complementarity determining region 2 of BV8S2 (V beta 8.2) contributes to antigen recognition by rat invariant NKT cell TCR.
Pyz E; Naidenko O; Miyake S; Yamamura T; Berberich I; Cardell S; Kronenberg M; Herrmann T
J Immunol; 2006 Jun; 176(12):7447-55. PubMed ID: 16751390
[TBL] [Abstract][Full Text] [Related]
17. The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells.
Kitamura H; Iwakabe K; Yahata T; Nishimura S; Ohta A; Ohmi Y; Sato M; Takeda K; Okumura K; Van Kaer L; Kawano T; Taniguchi M; Nishimura T
J Exp Med; 1999 Apr; 189(7):1121-8. PubMed ID: 10190903
[TBL] [Abstract][Full Text] [Related]
18. NKT cell-stimulating synthetic glycolipids as potential therapeutics for autoimmune disease.
Yamamura T; Miyamoto K; Illés Z; Pál E; Araki M; Miyake S
Curr Top Med Chem; 2004; 4(5):561-7. PubMed ID: 14965307
[TBL] [Abstract][Full Text] [Related]
19. Immunoregulation of autoimmunity by natural killer T cells.
Linsen L; Somers V; Stinissen P
Hum Immunol; 2005 Dec; 66(12):1193-202. PubMed ID: 16690406
[TBL] [Abstract][Full Text] [Related]
20. Innate Valpha14(+) natural killer T cells mature dendritic cells, leading to strong adaptive immunity.
Fujii S; Shimizu K; Hemmi H; Steinman RM
Immunol Rev; 2007 Dec; 220():183-98. PubMed ID: 17979847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
